Case 1 Additional glucose-lowering drug to reach glycaemic target in cardiac patient

Prattichizzo, Francesco, PhD, IRCCS MultiMedica, Milan, Italy
La Sala, Lucia, PhD, IRCCS MultiMedica, Milan, Italy
Prof. Ceriello, Antonio MD, IRCCS MultiMedica, Milan, Italy

04 May 2020

Lucia La Sala

Antonio Ceriello

Francesco Prattichizzo

The case

Carlo S. is a 65-year-old male with a history of myocardial infarction. Weighing 89kg for 172 cm, his last records show a blood pressure at 145/92mmHg, a total cholesterol at 180 mg/dl and a level for glycated haemoglobin at 8.4 %. He has suffered from type 2 diabetes (T2DM) for 10 years. As medication, Carlo uses metformin 1g/day, beta-blocker, statin, antiplatelet, ACE inhibitor.

Test your knowledge

References

Question 1:

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V,
et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41:255-323.
Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019 Mar 11;18(1):30.
Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201.

Question 2:

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V,et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 202041:255-323.
Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39.

Show navigation Hide navigation